EPHEDRINE THRESHOLD ELIMINATION PROPOSAL BY DEA WILL CREATE "DE FACTO BAN"
This article was originally published in The Tan Sheet
Executive Summary
EPHEDRINE THRESHOLD ELIMINATION PROPOSAL BY DEA WILL CREATE "DE FACTO BAN" of single-entity ephedrine sold in OTC bronchodilators, BDI Pharmaceuticals maintained in April 29 comments to the Drug Enforcement Administration. The company objected to a proposal published by DEA in the March 17 Federal Register to eliminate the regulatory threshold that currently exempts the sale of certain amounts of ephedrine from reporting and recordkeeping requirements under the Controlled Substances Act.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning